The acute pancreatitis market size is projected to reach US$ 8,827.37 million by 2030 from US$ 5,649.77 million in 2022. The market is expected to register a CAGR of 5.7% during 2022–2030. Advancements in specific acute pancreatitis treatments are likely to serve as one of the key trends in the market.
Several factors fuel the acute pancreatitis market growth, including the rising prevalence of diabetes, advances in diagnostic tools, and the development of novel treatment options. Obesity, consumption of alcohol, gallstones, and some medications have collectively contributed to a rise in the incidence of acute pancreatitis globally. Key market players invest in clinical trials, strategic alliances, and collaborations to strengthen their product portfolios and acquire a competitive advantage. The industry is being pushed by rising prevalence and demand for better treatment options. Ongoing research and development efforts and collaborative approaches are also expected to foster innovation and enhance outcomes for acute pancreatitis patients, thereby boosting the growth of the acute pancreatitis market during the forecast period.
A targeted novel treatment strategy that halts disease progression and improves patient outcomes is needed to address the current disease burden of acute and severe acute pancreatitis. An article published in the National Library of Medicine in February 2023 focuses on three major approaches to advance acute pancreatitis treatments—the clinical identification and application of new genetic information; newly identified serum biomarkers, i.e., fatty acid ethyl esters (FAEEs); and acceleration in timing of early nutrition feedings in acute pancreatitis. Such developments in specific treatment approaches would lead to new treatment options to enhance outcomes and improve the acute pancreatitis market during the forecast period.
The pancreas produces insulin, a hormone that regulates blood sugar levels. Pancreatitis can harm insulin-producing cells of the pancreas, which causes diabetes in patients suffering from acute pancreatitis. Pancreatogenic diabetes is increasingly being linked to exocrine disorders of the pancreas. As per the European Review for Medical and Pharmacological Sciences, published in 2022, the prevalence of pancreatogenic diabetes is 5–10% in the Western diabetic population, and chronic pancreatitis is responsible for 20% of cases, while acute pancreatitis causes 80% of cases. According to an article published in the National Library of Medicine in 2021, ~23% of acute pancreatitis patients are likely to develop diabetes within three years of discharge. Thus, the increasing incidence of diabetes in patients suffering or recovering from acute pancreatitis contributes to the growth of the acute pancreatitis market.
Several ongoing international efforts are being made to define the epidemiology and pathophysiology of acute pancreatitis. The National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) formed a collaborative network of 10 clinical centers and 1 data coordination center in 2020 to address several knowledge gaps regarding acute pancreatitis. The consortium is referred to as Type 1 Diabetes after Acute Pancreatitis Consortium (T1DAPC). Thus, awareness programs on acute pancreatitis for the development of effective therapies (through direct and indirect means) are expected to provide lucrative opportunities for companies in the acute pancreatitis market.
Key segments that contributed to the derivation of the acute pancreatitis market analysis are offerings, causes, and end user.
The geographic scope of the acute pancreatitis market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America has dominated the acute pancreatitis market. The growth of the market in this region is attributed to a high incidence of risk factors such as obesity and consumption of alcohol, modern healthcare infrastructure, and strong government campaigns promoting early detection and treatment. According to the 2021 National Survey on Drug Use and Health, ~174.3 million people in the US aged 12 and above consumed alcohol in 2020. According to Medscape data, ~40–50 acute pancreatitis cases per 100,000 adults are registered in the US annually. Nearly 275,000 hospital admissions in the US are due to acute pancreatitis. In addition, the region also has several key market players, such as pharmaceutical corporations and medical device manufacturers, who are actively involved in research and development to create innovative new and novel products in the market, thereby supporting the market growth in the region. Further, Asia Pacific is projected to grow with the highest CAGR in the coming years.
The regional trends and factors influencing the Acute Pancreatitis Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Acute Pancreatitis Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 5,649.77 Million |
| Market Size by 2030 | US$ 8,827.37 Million |
| Global CAGR (2022 - 2030) | 5.7% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Offerings
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Acute Pancreatitis Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Acute Pancreatitis Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The acute pancreatitis market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the acute pancreatitis market are listed below:
The “Acute Pancreatitis Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:
The estimated value of the acute pancreatitis market accounted for US$ 8,827.37 million in 2030.
The global acute pancreatitis market is estimated to register a CAGR of 5.7% during the forecast period 2022–2030.
North America region dominated the acute pancreatitis market in 2022.
The rise in pancreatic cancer cases due to acute pancreatitis and rising incidences of diabetes following acute pancreatitis are the most influential factors responsible for market growth.
Abbott Laboratories, GE HealthCare Technologies Inc, Samsung Healthcare, Koninklijke Philips NV, Baxter International Inc, Dynavax Technologies Corp, Actim Oy, Medtronic Plc, Boston Scientific Corp, and Fresenius Kabi AG are the market players in the acute pancreatitis market.